Introduktion
Den här sidan ger en omfattande analys av den kända insiderhandelshistoriken för Klaus R Dr Veitinger. Insiders är tjänstemän, styrelseledamöter eller betydande investerare i ett företag. Det är olagligt för insiders att göra affärer i sina företag baserat på specifik, icke-offentlig information. Detta betyder inte att det är olagligt för dem att göra några affärer i sina egna företag. De måste dock rapportera alla affärer till SEC via ett formulär 4. Trots dessa restriktioner tyder akademisk forskning på att insiders – i allmänhet – tenderar att överträffa marknaden i sina egna företag.
Genomsnittlig handelslönsamhet
Den genomsnittliga handelslönsamheten är den genomsnittliga avkastningen av alla köp på den öppna marknaden som insidern gjort under de senaste tre åren. För att beräkna detta undersöker vi alla oplanerade köp på öppen marknad som görs av insidern, exklusive alla affärer som markerats som en del av en 10b5-1-handelsplan. Vi beräknar sedan den genomsnittliga prestandan för dessa affärer under 3, 6 och 12 månader, med ett genomsnitt av var och en av dessa varaktigheter för att generera ett slutgiltigt resultatmått för varje affär. Slutligen tar vi ett genomsnitt av alla prestationsmått för att beräkna ett prestationsmått för insidern. Denna lista inkluderar endast insiders som har gjort minst tre affärer under de senaste två åren.
Om lönsamheten för denna insiderhandel är "N/A", så har insidern antingen inte gjort några köp på den öppna marknaden under de senaste tre åren, eller så är affärerna de har gjort för nya för att kunna beräkna ett tillförlitligt resultatmått.
Uppdateringsfrekvens: Dagligen
Företag med rapporterade insiderpositioner
SEC-anmälningarna visar att Klaus R Dr Veitinger har rapporterat innehav eller affärer i följande företag:
Värdepapper | Titel | Senaste rapporterade innehav |
---|---|---|
US:TCDA / Tricida Inc | Director | 57 235 |
US:SCPH / scPharmaceuticals Inc. | Director | 16 300 |
US:ICPT / Intercept Pharmaceuticals Inc | Director | 1 750 |
US:RLYP / Relypsa, Inc. | Director | 69 543 |
Hur man tolkar diagrammen
Följande diagram visar aktieutvecklingen för värdepapper efter varje icke-planerad handel på öppen marknad som görs av Klaus R Dr Veitinger. Icke-planerad handel är affärer som inte gjordes som en del av en 10b5-1-handelsplan. Aktieutvecklingen visas som kumulativ procentuell förändring av aktiekursen. Till exempel, om en insiderhandel gjordes den 1 januari 2019, kommer diagrammet att visa den dagliga procentuella förändringen av värdepapperet fram till idag. Om aktiekursen skulle gå från $10 till $15 under denna tid, skulle den kumulativa procentuella förändringen i aktiekursen vara 50%. En förändring i priset från 10 USD till 20 USD skulle vara 100 % och en prisändring på 10 USD till 5 USD skulle vara -50 %.
I slutändan försöker vi avgöra hur nära insiders affärer korrelerar med överavkastning (positiv eller negativ) i aktiekursen för att se om insidern tar tid för sina affärer att dra nytta av insiderinformation. Tänk på situationen där en insider gjorde detta. I den här situationen förväntar vi oss antingen (a) positiv avkastning efter köp eller (b) negativ avkastning efter försäljning. I fallet med (a) skulle KÖP-diagrammet visa en serie uppåtlutande kurvor, vilket indikerar positiv avkastning efter varje köptransaktion. I fallet med (b) skulle SALE-diagrammet visa en serie nedåtlutande kurvor, vilket indikerar negativ avkastning efter varje försäljningstransaktion.
Detta är dock inte tillräckligt för att dra slutsatser. Om till exempel aktiekursen i bolaget var i en icke-cyklisk stigning under många år, skulle vi förvänta oss att alla tomter efter köpet skulle vara uppåtlutande. Likaså skulle icke-cykliska nedgångar under många år resultera i nedåtlutande post-trade tomter. Inget av dessa diagram skulle tyda på insiderhandel.
Den starkaste indikatorn skulle vara en situation där aktiekursen var extremt cyklisk, och det fanns både positiva signaler i KÖP-diagrammet och negativa plotter på SALE-diagrammet. Denna situation skulle i hög grad tyda på en insider som tog tid för affärer till sin ekonomiska fördel.
Insiderköp SCPH / scPharmaceuticals Inc. - Analys av kortsiktig vinst
I det här avsnittet analyserar vi lönsamheten för varje oplanerat insiderköp på en öppen marknad som görs i SCPH / scPharmaceuticals Inc.. Denna analys hjälper till att förstå om insidern konsekvent genererar onormal avkastning och är värd att följa. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Tabellen nedan visar de senaste öppna marknadsköpen som inte var en del av en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till max |
Pris vid max |
Max vinst ($) |
Maximal avkastning (%) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderförsäljning - Analys av kortsiktig förlust
I det här avsnittet analyserar vi det kortsiktiga undvikandet av förluster för varje oplanerad insiderförsäljning på öppen marknad som görs i SCPH / scPharmaceuticals Inc.. Ett konsekvent mönster för att undvika förluster kan tyda på att framtida försäljningstransaktioner kan förutsäga prisnedgångar. Denna analys är för ett år efter varje handel, och resultaten är teoretiska .
Följande tabell visar de senaste försäljningarna på den öppna marknaden som inte ingick i en automatisk handelsplan.
Handelsdatum | Ticker | Insider | Rapporterade aktier |
Rapporterad pris |
Justerade aktier |
Justerat pris |
Kostnadsgrund | Dagar till min |
Pris vid min |
Maximal förlust undvikits ($) |
Maximal förlust undvikits ($) |
---|---|---|---|---|---|---|---|
Det finns inga kända oplanerade öppna marknadstransaktioner för denna insider |
Det justerade prisetär det justerade priset efter split. Justerade aktier er de split-justerade aktier.
Insiderhandelshistorik
Den här tabellen visar den fullständiga listan över insideraffärer gjorda av Klaus R Dr Veitinger som avslöjats för Securities Exchange Commission (SEC).
Fildatum | Transaktionsdatum | Schema | Ticker | Värdepapper | Kode | Aktier | Återstående aktier | Procentuell förandring | Aktie pris |
Transaktionsvärde | Återstående värde |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2021-06-11 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
A - Award | 57 235 | 57 235 | |||||
2021-06-11 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
A - Award | 16 403 | 27 584 | 146,70 | ||||
2021-06-10 |
|
4 | SCPH |
scPharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 16 300 | 16 300 | |||||
2021-02-09 |
|
5 | TCDA |
Tricida, Inc.
Common Stock |
G - Gift | −35 804 | 11 181 | −76,20 | ||||
2020-06-15 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
A - Award | 22 967 | 22 967 | |||||
2020-06-15 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
A - Award | 5 670 | 46 985 | 13,72 | ||||
2020-06-11 |
|
4 | SCPH |
scPharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 6 124 | 6 124 | |||||
2019-11-05 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 750 | 0 | −100,00 | ||||
2019-11-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 51 444 | −3,29 | 38,87 | −68 022 | 1 999 628 |
2019-11-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 51 444 | −3,29 | 38,88 | −68 040 | 2 000 143 |
2019-11-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 51 444 | −3,29 | 38,88 | −68 040 | 2 000 143 |
2019-11-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 750 | 43 065 | 4,24 | 0,80 | 1 400 | 34 452 | |
2019-10-29 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 750 | 1 750 | −50,00 | ||||
2019-10-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 53 194 | −3,19 | 36,29 | −63 508 | 1 930 410 |
2019-10-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 53 194 | −3,19 | 36,30 | −63 525 | 1 930 942 |
2019-10-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 750 | 41 315 | −4,06 | 36,31 | −63 542 | 1 500 148 |
2019-10-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 750 | 43 065 | 4,24 | 0,80 | 1 400 | 34 452 | |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 400 | 3 500 | −28,57 | ||||
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −103 | 54 944 | −0,19 | 32,47 | −3 344 | 1 784 032 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −573 | 55 047 | −1,03 | 32,12 | −18 405 | 1 768 110 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −724 | 55 620 | −1,28 | 30,72 | −22 241 | 1 708 646 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −153 | 54 944 | −0,28 | 32,42 | −4 960 | 1 781 284 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −570 | 55 097 | −1,02 | 32,01 | −18 246 | 1 763 655 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −677 | 55 667 | −1,20 | 30,72 | −20 797 | 1 710 090 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −121 | 41 315 | −0,29 | 32,45 | −3 926 | 1 340 672 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −585 | 41 436 | −1,39 | 32,05 | −18 749 | 1 328 024 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −694 | 42 021 | −1,62 | 30,66 | −21 278 | 1 288 364 |
2019-09-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 400 | 42 715 | 3,39 | 0,80 | 1 120 | 34 172 | |
2019-08-28 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 400 | 4 900 | −22,22 | ||||
2019-08-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 56 344 | −2,42 | 33,17 | −46 438 | 1 868 930 |
2019-08-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 56 344 | −2,42 | 33,14 | −46 396 | 1 867 240 |
2019-08-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 41 315 | −3,28 | 33,18 | −46 452 | 1 370 832 |
2019-08-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 400 | 42 715 | 3,39 | 0,80 | 1 120 | 34 172 | |
2019-07-29 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 400 | 6 300 | −18,18 | ||||
2019-07-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 57 744 | −2,37 | 31,64 | −44 296 | 1 827 020 |
2019-07-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 57 744 | −2,37 | 31,62 | −44 268 | 1 825 865 |
2019-07-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 400 | 41 315 | −3,28 | 31,61 | −44 254 | 1 305 967 |
2019-07-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 400 | 42 715 | 3,39 | 0,80 | 1 120 | 34 172 | |
2019-07-09 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −1 100 | 7 700 | −12,50 | ||||
2019-07-09 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 200 | 59 144 | −1,99 | 36,30 | −43 560 | 2 146 927 |
2019-07-09 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 192 | 59 144 | −1,98 | 36,30 | −43 270 | 2 146 927 |
2019-07-09 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −1 100 | 41 315 | −2,59 | 36,29 | −39 919 | 1 499 321 |
2019-07-09 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 1 100 | 42 415 | 2,66 | 0,80 | 880 | 33 932 | |
2019-07-05 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −3 100 | 8 800 | −26,05 | ||||
2019-07-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 000 | 60 344 | −4,74 | 36,91 | −110 730 | 2 227 297 |
2019-07-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 008 | 60 336 | −4,75 | 36,89 | −110 965 | 2 225 795 |
2019-07-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 100 | 41 315 | −6,98 | 36,91 | −114 421 | 1 524 937 |
2019-07-05 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 3 100 | 44 415 | 7,50 | 0,80 | 2 480 | 35 532 | |
2019-06-20 |
|
4 | SCPH |
scPharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 6 124 | 6 124 | |||||
2019-06-04 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
A - Award | 7 068 | 7 068 | |||||
2019-06-04 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
A - Award | 1 879 | 41 315 | 4,76 | ||||
2019-03-29 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −22 100 | 11 900 | −65,00 | ||||
2019-03-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −22 100 | 63 344 | −25,86 | 34,18 | −755 378 | 2 165 098 |
2019-03-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −22 100 | 63 344 | −25,86 | 34,19 | −755 599 | 2 165 731 |
2019-03-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −22 100 | 63 344 | −25,86 | 34,19 | −755 599 | 2 165 731 |
2019-03-29 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 22 100 | 61 536 | 56,04 | 0,80 | 17 680 | 49 229 | |
2019-03-28 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −4 000 | 34 000 | −10,53 | ||||
2019-03-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 85 444 | −4,47 | 23,80 | −95 200 | 2 033 567 |
2019-03-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 85 444 | −4,47 | 23,84 | −95 360 | 2 036 985 |
2019-03-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 39 436 | −9,21 | 23,85 | −95 400 | 940 549 |
2019-03-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 4 000 | 43 436 | 10,14 | 0,80 | 3 200 | 34 749 | |
2019-02-27 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −4 000 | 38 000 | −9,52 | ||||
2019-02-27 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 89 444 | −4,28 | 22,59 | −90 360 | 2 020 540 |
2019-02-27 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 89 444 | −4,28 | 22,60 | −90 400 | 2 021 434 |
2019-02-27 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −4 000 | 89 444 | −4,28 | 22,60 | −90 400 | 2 021 434 |
2019-02-27 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 4 000 | 43 436 | 10,14 | 0,80 | 3 200 | 34 749 | |
2019-01-30 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −2 000 | 42 000 | −4,55 | 0,80 | −1 600 | 33 600 | |
2019-01-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 93 444 | −2,10 | 20,33 | −40 660 | 1 899 717 |
2019-01-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 93 444 | −2,10 | 20,32 | −40 640 | 1 898 782 |
2019-01-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 39 436 | −4,83 | 20,29 | −40 580 | 800 156 |
2019-01-30 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 2 000 | 41 436 | 5,07 | 0,80 | 1 600 | 33 149 | |
2019-01-28 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −2 000 | 44 000 | −4,35 | ||||
2019-01-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 95 444 | −2,05 | 20,86 | −41 720 | 1 990 962 |
2019-01-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 95 444 | −2,05 | 20,88 | −41 760 | 1 992 871 |
2019-01-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −2 000 | 39 436 | −4,83 | 20,85 | −41 700 | 822 241 |
2019-01-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 2 000 | 41 436 | 5,07 | 0,80 | 1 600 | 33 149 | |
2018-12-31 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −997 | 46 000 | −2,12 | ||||
2018-12-31 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −740 | 97 444 | −0,75 | 23,74 | −17 568 | 2 313 321 |
2018-12-31 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −700 | 97 444 | −0,71 | 23,78 | −16 646 | 2 317 218 |
2018-12-31 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −997 | 39 436 | −2,47 | 23,63 | −23 559 | 931 873 |
2018-12-31 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 997 | 40 433 | 2,53 | 0,80 | 798 | 32 346 | |
2018-12-28 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
M - Exercise | −3 254 | 46 997 | −6,48 | ||||
2018-12-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 260 | 98 184 | −3,21 | 24,97 | −81 402 | 2 451 654 |
2018-12-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 300 | 98 144 | −3,25 | 24,97 | −82 401 | 2 450 656 |
2018-12-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
S - Sale | X | −3 254 | 39 436 | −7,62 | 24,97 | −81 252 | 984 717 |
2018-12-28 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
M - Exercise | 3 254 | 42 690 | 8,25 | 0,80 | 2 603 | 34 152 | |
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Stock Option (right to buy) |
A - Award | 13 147 | 13 147 | |||||
2018-07-02 |
|
4 | TCDA |
Tricida, Inc.
Common Stock |
A - Award | 3 632 | 39 436 | 10,14 | ||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
274 496 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
274 496 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
274 496 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-27 | 3 | TCDA |
Tricida, Inc.
Common Stock |
340 136 | ||||||||
2018-06-21 |
|
4 | SCPH |
scPharmaceuticals Inc.
Stock Option (Right to Buy) |
A - Award | 6 124 | 6 124 | |||||
2015-11-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 1 750 | 1 750 | |||||
2015-11-27 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 650 | 2 816 | 30,01 | ||||
2015-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −1 000 | 5 972 | −14,34 | |||
2015-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −1 000 | 2 166 | −31,59 | 198,25 | −198 250 | 429 410 |
2015-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 1 000 | 3 166 | 46,17 | 21,50 | 21 500 | 68 069 |
2015-09-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −500 | 6 972 | −6,69 | |||
2015-09-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −500 | 2 166 | −18,75 | 198,25 | −99 125 | 429 410 |
2015-09-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 500 | 2 666 | 23,08 | 21,50 | 10 750 | 57 319 |
2015-08-05 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −500 | 7 472 | −6,27 | |||
2015-08-05 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −500 | 2 166 | −18,75 | 261,17 | −130 585 | 565 694 |
2015-08-05 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 500 | 2 666 | 23,08 | 21,50 | 10 750 | 57 319 |
2015-06-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 7 972 | −4,68 | |||
2015-06-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −391 | 2 166 | −15,29 | 238,21 | −93 140 | 515 963 |
2015-06-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2015-05-13 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −5 834 | 69 543 | −7,74 | ||||
2015-05-13 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −5 834 | 2 712 | −68,27 | 36,06 | −210 387 | 97 801 |
2015-05-13 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 5 834 | 8 546 | 215,12 | 3,96 | 23 103 | 33 842 | |
2015-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 8 363 | −4,47 | |||
2015-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 166 | −9,71 | 283,33 | −66 016 | 613 694 |
2015-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −158 | 2 399 | −6,18 | 272,79 | −43 101 | 654 423 |
2015-05-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2015-04-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 8 754 | −4,28 | |||
2015-04-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −391 | 2 166 | −15,29 | 272,10 | −106 391 | 589 369 |
2015-04-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2015-04-13 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −5 832 | 75 377 | −7,18 | ||||
2015-04-13 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −5 832 | 2 712 | −68,26 | 35,35 | −206 179 | 95 877 |
2015-04-13 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 5 832 | 8 544 | 215,04 | 3,96 | 23 095 | 33 834 | |
2015-03-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −2 503 | 81 209 | −2,99 | ||||
2015-03-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −3 331 | 12 795 | −20,66 | ||||
2015-03-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −5 834 | 2 712 | −68,27 | 38,67 | −225 594 | 104 870 |
2015-03-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 2 503 | 8 546 | 41,42 | 3,96 | 9 912 | 33 842 | |
2015-03-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 3 331 | 6 043 | 122,82 | 4,65 | 15 489 | 28 100 | |
2015-03-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 9 145 | −4,10 | |||
2015-03-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −158 | 2 166 | −6,80 | 263,25 | −41 594 | 570 200 |
2015-03-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 324 | −9,11 | 261,25 | −60 871 | 607 145 |
2015-03-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2015-02-26 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −632 | 9 536 | −6,22 | |||
2015-02-26 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −632 | 2 166 | −22,59 | 222,50 | −140 620 | 481 935 |
2015-02-26 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 632 | 2 798 | 29,18 | 21,50 | 13 588 | 60 157 |
2015-02-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −233 | 10 168 | −2,24 | |||
2015-02-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 166 | −9,71 | 195,52 | −45 556 | 423 496 |
2015-02-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 233 | 2 399 | 10,76 | 21,50 | 5 010 | 51 578 |
2015-02-10 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −5 834 | 16 126 | −26,57 | ||||
2015-02-10 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −100 | 2 712 | −3,56 | 32,74 | −3 274 | 88 791 |
2015-02-10 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −5 734 | 2 812 | −67,10 | 32,10 | −184 085 | 90 277 |
2015-02-10 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 5 834 | 8 546 | 215,12 | 4,65 | 27 128 | 39 739 | |
2015-01-14 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −5 834 | 21 960 | −20,99 | ||||
2015-01-14 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −1 448 | 2 712 | −34,81 | 32,79 | −47 483 | 88 932 |
2015-01-14 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −4 386 | 4 160 | −51,32 | 32,17 | −141 106 | 133 835 |
2015-01-14 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 5 834 | 8 546 | 215,12 | 4,65 | 27 128 | 39 739 | |
2015-01-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −233 | 10 401 | −2,19 | |||
2015-01-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 166 | −9,71 | 150,01 | −34 952 | 324 922 |
2015-01-14 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 233 | 2 399 | 10,76 | 21,50 | 5 010 | 51 578 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −9 852 | 27 794 | −26,17 | ||||
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −9 852 | 2 712 | −78,41 | 32,50 | −320 190 | 88 140 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 9 852 | 12 564 | 363,27 | 4,65 | 45 812 | 58 423 | |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −150 | 37 646 | −0,40 | ||||
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −150 | 2 712 | −5,24 | 32,50 | −4 875 | 88 140 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 150 | 2 862 | 5,53 | 4,65 | 698 | 13 308 | |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −4 167 | 37 796 | −9,93 | ||||
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −263 | 2 712 | −8,84 | 32,20 | −8 468 | 87 324 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −3 104 | 2 975 | −51,06 | 31,52 | −97 841 | 93 775 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −800 | 6 079 | −11,63 | 30,38 | −24 307 | 184 703 |
2014-12-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 4 167 | 6 879 | 153,65 | 4,65 | 19 377 | 31 987 | |
2014-12-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −233 | 10 634 | −2,14 | |||
2014-12-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 166 | −9,71 | 144,16 | −33 589 | 312 251 |
2014-12-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 233 | 2 399 | 10,76 | 21,50 | 5 010 | 51 578 |
2014-11-24 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −3 334 | 41 963 | −7,36 | ||||
2014-11-24 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −3 334 | 2 712 | −55,14 | 22,50 | −75 015 | 61 020 |
2014-11-24 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 3 334 | 6 046 | 122,94 | 4,65 | 15 503 | 28 114 | |
2014-11-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −2 500 | 45 297 | −5,23 | ||||
2014-11-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −2 500 | 2 712 | −47,97 | 20,06 | −50 144 | 54 396 |
2014-11-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 2 500 | 5 212 | 92,18 | 4,65 | 11 625 | 24 236 | |
2014-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −233 | 10 867 | −2,10 | |||
2014-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 2 166 | −9,71 | 175,95 | −40 996 | 381 108 |
2014-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 233 | 2 399 | 10,76 | 21,50 | 5 010 | 51 578 |
2014-10-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 11 100 | −3,40 | |||
2014-10-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −391 | 2 166 | −15,29 | 223,65 | −87 447 | 484 426 |
2014-10-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2014-10-15 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −2 500 | 47 797 | −4,97 | ||||
2014-10-15 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −100 | 2 712 | −3,56 | 19,86 | −1 986 | 53 860 |
2014-10-15 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −2 400 | 2 812 | −46,05 | 19,32 | −46 357 | 54 315 |
2014-10-15 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 2 500 | 5 212 | 92,18 | 4,65 | 11 625 | 24 236 | |
2014-09-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −391 | 11 491 | −3,29 | |||
2014-09-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −391 | 2 166 | −15,29 | 280,50 | −109 676 | 607 563 |
2014-09-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2014-09-11 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −4 167 | 50 297 | −7,65 | ||||
2014-09-11 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −4 167 | 2 712 | −60,58 | 23,00 | −95 851 | 62 383 |
2014-09-11 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 4 167 | 6 879 | 153,65 | 4,65 | 19 377 | 31 987 | |
2014-08-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | X | −316 | 11 882 | −2,59 | |||
2014-08-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −316 | 2 166 | −12,73 | 345,62 | −109 216 | 748 613 |
2014-08-15 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 316 | 2 482 | 14,59 | 21,50 | 6 794 | 53 363 |
2014-08-12 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −4 167 | 54 464 | −7,11 | ||||
2014-08-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −4 167 | 2 712 | −60,58 | 27,73 | −115 563 | 75 212 |
2014-08-12 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 4 167 | 6 879 | 153,65 | 4,65 | 19 377 | 31 987 | |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
M - Exercise | −391 | 12 198 | −3,11 | ||||
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −391 | 2 166 | −15,29 | 239,49 | −93 641 | 518 735 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 557 | 18,05 | 21,50 | 8 406 | 54 976 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −1 | 2 166 | −0,05 | 238,28 | −238 | 516 114 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −93 | 2 167 | −4,12 | 238,26 | −22 158 | 516 309 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −6 | 2 260 | −0,26 | 238,25 | −1 430 | 538 445 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −64 | 2 266 | −2,75 | 234,71 | −15 021 | 531 853 |
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −324 | 0 | −100,00 | ||||
2014-08-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 324 | 2 330 | 16,15 | ||||
2014-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
A - Award | 275 | 275 | |||||
2014-07-21 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 226 | 2 006 | 12,70 | ||||
2014-07-11 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
M - Exercise | −4 167 | 58 631 | −6,64 | ||||
2014-07-11 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
S - Sale | X | −4 167 | 2 712 | −60,58 | 23,12 | −96 354 | 62 710 |
2014-07-11 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
M - Exercise | 4 167 | 6 879 | 153,65 | 4,65 | 19 377 | 31 987 | |
2014-07-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Option to Purchase Common Stock |
M - Exercise | X | −391 | 12 589 | −3,01 | |||
2014-07-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −158 | 1 780 | −8,15 | 222,50 | −35 155 | 396 050 |
2014-07-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −233 | 1 938 | −10,73 | 216,88 | −50 533 | 420 313 |
2014-07-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | X | 391 | 2 171 | 21,97 | 21,50 | 8 406 | 46 676 |
2014-06-23 |
|
4 | RLYP |
Relypsa Inc
Stock Option (right to buy) |
A - Award | 3 828 | 3 828 | |||||
2014-06-23 |
|
4 | RLYP |
Relypsa Inc
Common Stock |
A - Award | 2 712 | 2 712 | |||||
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −325 | 324 | −50,08 | ||||
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 1 780 | −5,32 | 232,35 | −23 235 | 413 587 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −62 | 1 880 | −3,19 | 228,69 | −14 179 | 429 937 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 325 | 1 942 | 20,10 | ||||
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −65 | 1 617 | −3,86 | 251,25 | −16 331 | 406 271 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 1 682 | −5,61 | 250,46 | −25 046 | 421 274 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 1 782 | −5,31 | 252,31 | −25 231 | 449 616 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 1 882 | −5,05 | 255,91 | −25 591 | 481 623 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 1 982 | −4,80 | 254,00 | −25 400 | 503 428 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 2 082 | −4,58 | 254,09 | −25 409 | 529 015 |
2014-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 2 182 | −4,38 | 261,42 | −26 142 | 570 418 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −52 | 2 282 | −2,23 | 385,04 | −20 022 | 878 661 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −1 | 2 334 | −0,04 | 385,00 | −385 | 898 590 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −1 | 2 335 | −0,04 | 384,77 | −385 | 898 438 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −7 | 2 336 | −0,30 | 384,33 | −2 690 | 897 795 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −1 | 2 343 | −0,04 | 374,09 | −374 | 876 493 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 2 344 | −4,09 | 373,34 | −37 334 | 875 109 |
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −324 | 649 | −33,30 | ||||
2014-02-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 324 | 2 444 | 15,28 | ||||
2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −100 | 2 120 | −4,50 | 49,01 | −4 901 | 103 901 |
2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
S - Sale | X | −62 | 2 220 | −2,72 | 48,81 | −3 026 | 108 358 |
2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −325 | 973 | −25,04 | ||||
2013-11-12 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 325 | 2 282 | 16,61 | ||||
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −71 | 1 957 | −3,50 | 75,00 | −5 325 | 146 775 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 028 | −4,70 | 74,89 | −7 489 | 151 877 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 128 | −4,49 | 74,76 | −7 476 | 159 100 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 228 | −4,30 | 74,25 | −7 425 | 165 429 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 328 | −4,12 | 73,57 | −7 357 | 171 271 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 428 | −3,96 | 72,64 | −7 264 | 176 358 |
2013-10-03 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
S - Sale | X | −100 | 2 528 | −3,81 | 69,26 | −6 926 | 175 077 |
2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −325 | 1 298 | −20,02 | ||||
2013-08-13 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 325 | 2 628 | 14,11 | ||||
2013-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −324 | 1 623 | −16,64 | ||||
2013-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
M - Exercise | 324 | 973 | 49,92 | ||||
2013-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
A - Award | 1 980 | 1 980 | |||||
2013-05-09 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common Stock |
A - Award | 1 330 | 2 303 | 136,69 | ||||
2013-04-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
M - Exercise | −649 | 1 947 | −25,00 | ||||
2013-04-11 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Common stock |
M - Exercise | 649 | 649 | |||||
2012-11-20 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Options to Purchase Common Stock |
A - Award | 12 980 | 12 980 | |||||
2012-11-20 |
|
4 | ICPT |
INTERCEPT PHARMACEUTICALS INC
Restricted Stock Units |
A - Award | 2 596 | 2 596 |